Monoclonal Antibodies for Treatment of Cancer
AssigneesGanymed Pharmaceuticals AG, Johannes Gutenberg-Universitat Mainz
InventorsUgur Sahin, Michael Koslowski, Ozlem Tureci
Life of this patent
Estimating the term…
Abstract
The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, and hepatocellular cancer.
Claims25
-35. (canceled)
An isolated antibody having the ability of binding to a protein comprising the amino acid sequence of SEQ ID NO:
- 2 and mediating inhibition of proliferation of cells, wherein said cells express a protein comprising the amino acid sequence of SEQ ID NO:
- 2 and/or are characterized by association of a protein comprising the amino acid sequence of SEQ ID NO:
- 2 with their cell surface.
An isolated antibody produced by a clone deposited under the accession no. DSM ACC2826 (9B6-2A9), DSM ACC2824 (59D6-2F2), DSM ACC2823 (78H11-1H6), DSM ACC2895 (22-1A-1), DSM ACC2893 (22-2A-1), DSM ACC2896 (22-9B-1), DSM ACC2897 (23-33A-1), DSM ACC2891 (23-19A-1), DSM ACC2892 (4A12 2D4 1A1 0), or DSM ACC2898 (4E9 1D12 2D4).
A hybridoma deposited under the accession no. DSM ACC2826 (9B6-2A9), DSM ACC2824 (59D6-2F2), DSM ACC2823 (78H11-1H6), DSM ACC2895 (22-1A-1), DSM ACC2893 (22-2A-1), DSM ACC2896 (22-9B-1), DSM ACC2897 (23-33A-1), DSM ACC2891 (23-19A-1), DSM ACC2892 (4A12 2D4 1A10), or DSM ACC2898 (4E9 1D12 2D4).
Dependencies are inferred from the claim text.